Expression of IL17A in endometrial carcinoma and effects of IL17A on biological behaviour in Ishikawa cells. Issue 9 (September 2020)

• Record Type: Journal Article
• Authors: Cheng, Ran; Xue, Xiaoou; Liu, Xiaoli
• Is Part Of: Journal of international medical research. Volume 48:Issue 9(2020)
• Publication Date: 2020-09
• Subjects: Endometrial cancer -- interleukin 17A -- proliferation -- migration; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060520950563
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: A growing body of evidence suggests chronic inflammation triggers the process of endometrial carcinogenesis. Interleukin (IL) 17A is an important proinflammatory factor involved in the tumour angiogenesis processes of many solid tumours. This study aimed to characterize the function of IL17A in endometrioid-type endometrial carcinoma. Methods: Levels of IL17A in human endometrial tissues were analysed by immunohistochemistry. In vitro proliferation and migration were analysed in Ishikawa cells treated with IL17A, using cell counting kit-8, wound healing and transwell assays. Western blots were used to analyse levels of oestrogen receptor (ER)α and ERβ proteins in Ishikawa cells treated with IL17A. Results: IL17A levels were significantly higher in endometrial carcinoma tissues than in endometrial hyperplasic tissues. Significantly increased proliferation and migration was observed in Ishikawa cells treated with IL17A versus controls. Investigation of the molecular mechanism revealed that IL17A treatment upregulated the ERα/ERβ protein ratio in Ishikawa cells. Conclusions: IL17A may be an important proinflammatory factor involved in promoting endometrial carcinogenesis.